Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome

Rie Yoshida, Tomonobu Hasegawa, Yukihiro Hasegawa, Toshiro Nagai, Eiichi Kinoshita, Yoko Tanaka, Hirokazu Kanegane, Kenji Ohyama, Toshikazu Onishi, Kunihiko Hanew, Torayuki Okuyama, Reiko Horikawa, Toshiaki Tanaka, Tsutomu Ogata

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

We report on PTPN11 (protein-tyrosine phosphatase, nonreceptor type 11) mutation analysis and clinical assessment in 45 patients with Noonan syndrome. Sequence analysis was performed for all of the coding esons 1-15 of PTPN11, revealing a novel 3-bp deletion mutation and 10 recurrent missense mutations in 18 patients. Clinical assessment showed that 1) the growth pattern was similar in mutation-positive and mutation-negative patients, with no significant difference in birth length [-0.6 ± 2.2 SD (n = 10) vs. -0.6 ± 1.4 SD (n = 21); P = 0.95], childhood height [-2.6 ± 1.1 SD (n = 14) vs. -2.1 ± 1.6 SD (n = 23); P = 0.28], or target height [-0.4 ± 0.9 SD (n = 14) vs. -0.2 ± 0.7 SD (n = 17); P = 0.52]; 2) pulmonary valve stenosis was more frequent in mutation-positive patients than in mutation-negative patients (10 of 18 vs. 6 of 27; P = 0.02), as was atrial septal defect (10 of 18 vs. 4 of 27; P = 0.005), whereas hypertrophic cardiomyopathy was present in five mutation-negative patients only; and 3) other features were grossly similar in the prevalence between mutation-positive and mutation-negative patients, but hematological abnormalities, such as bleeding diathesis and juvenile myelomonocytic leukemia, were exclusively present in mutation-positive patients (5 of 18 vs. 0 of 27; P = 0.007). The results suggest that PTPN11 mutations account for approximately 40% of Noonan syndrome patients, as has been reported previously. Furthermore, assessment of clinical features, in conjunction with data reported previously, implies that the type of cardiovascular lesions and the occurrence of hematological abnormalities are different in mutation-positive and mutation-negative patients, whereas the remaining findings are similar in the two groups of patients.

Original languageEnglish
Pages (from-to)3359-3364
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number7
DOIs
Publication statusPublished - 2004 Jul

Fingerprint

Noonan Syndrome
Protein Tyrosine Phosphatases
Mutation
Defects
Juvenile Myelomonocytic Leukemia
Pulmonary Valve Stenosis
Atrial Heart Septal Defects
Sequence Deletion
Hypertrophic Cardiomyopathy
Disease Susceptibility
Missense Mutation
Sequence Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. / Yoshida, Rie; Hasegawa, Tomonobu; Hasegawa, Yukihiro; Nagai, Toshiro; Kinoshita, Eiichi; Tanaka, Yoko; Kanegane, Hirokazu; Ohyama, Kenji; Onishi, Toshikazu; Hanew, Kunihiko; Okuyama, Torayuki; Horikawa, Reiko; Tanaka, Toshiaki; Ogata, Tsutomu.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 7, 07.2004, p. 3359-3364.

Research output: Contribution to journalArticle

Yoshida, R, Hasegawa, T, Hasegawa, Y, Nagai, T, Kinoshita, E, Tanaka, Y, Kanegane, H, Ohyama, K, Onishi, T, Hanew, K, Okuyama, T, Horikawa, R, Tanaka, T & Ogata, T 2004, 'Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome', Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 7, pp. 3359-3364. https://doi.org/10.1210/jc.2003-032091
Yoshida, Rie ; Hasegawa, Tomonobu ; Hasegawa, Yukihiro ; Nagai, Toshiro ; Kinoshita, Eiichi ; Tanaka, Yoko ; Kanegane, Hirokazu ; Ohyama, Kenji ; Onishi, Toshikazu ; Hanew, Kunihiko ; Okuyama, Torayuki ; Horikawa, Reiko ; Tanaka, Toshiaki ; Ogata, Tsutomu. / Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 7. pp. 3359-3364.
@article{6582e8778a9d4a07b3d024efa9095259,
title = "Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome",
abstract = "We report on PTPN11 (protein-tyrosine phosphatase, nonreceptor type 11) mutation analysis and clinical assessment in 45 patients with Noonan syndrome. Sequence analysis was performed for all of the coding esons 1-15 of PTPN11, revealing a novel 3-bp deletion mutation and 10 recurrent missense mutations in 18 patients. Clinical assessment showed that 1) the growth pattern was similar in mutation-positive and mutation-negative patients, with no significant difference in birth length [-0.6 ± 2.2 SD (n = 10) vs. -0.6 ± 1.4 SD (n = 21); P = 0.95], childhood height [-2.6 ± 1.1 SD (n = 14) vs. -2.1 ± 1.6 SD (n = 23); P = 0.28], or target height [-0.4 ± 0.9 SD (n = 14) vs. -0.2 ± 0.7 SD (n = 17); P = 0.52]; 2) pulmonary valve stenosis was more frequent in mutation-positive patients than in mutation-negative patients (10 of 18 vs. 6 of 27; P = 0.02), as was atrial septal defect (10 of 18 vs. 4 of 27; P = 0.005), whereas hypertrophic cardiomyopathy was present in five mutation-negative patients only; and 3) other features were grossly similar in the prevalence between mutation-positive and mutation-negative patients, but hematological abnormalities, such as bleeding diathesis and juvenile myelomonocytic leukemia, were exclusively present in mutation-positive patients (5 of 18 vs. 0 of 27; P = 0.007). The results suggest that PTPN11 mutations account for approximately 40{\%} of Noonan syndrome patients, as has been reported previously. Furthermore, assessment of clinical features, in conjunction with data reported previously, implies that the type of cardiovascular lesions and the occurrence of hematological abnormalities are different in mutation-positive and mutation-negative patients, whereas the remaining findings are similar in the two groups of patients.",
author = "Rie Yoshida and Tomonobu Hasegawa and Yukihiro Hasegawa and Toshiro Nagai and Eiichi Kinoshita and Yoko Tanaka and Hirokazu Kanegane and Kenji Ohyama and Toshikazu Onishi and Kunihiko Hanew and Torayuki Okuyama and Reiko Horikawa and Toshiaki Tanaka and Tsutomu Ogata",
year = "2004",
month = "7",
doi = "10.1210/jc.2003-032091",
language = "English",
volume = "89",
pages = "3359--3364",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome

AU - Yoshida, Rie

AU - Hasegawa, Tomonobu

AU - Hasegawa, Yukihiro

AU - Nagai, Toshiro

AU - Kinoshita, Eiichi

AU - Tanaka, Yoko

AU - Kanegane, Hirokazu

AU - Ohyama, Kenji

AU - Onishi, Toshikazu

AU - Hanew, Kunihiko

AU - Okuyama, Torayuki

AU - Horikawa, Reiko

AU - Tanaka, Toshiaki

AU - Ogata, Tsutomu

PY - 2004/7

Y1 - 2004/7

N2 - We report on PTPN11 (protein-tyrosine phosphatase, nonreceptor type 11) mutation analysis and clinical assessment in 45 patients with Noonan syndrome. Sequence analysis was performed for all of the coding esons 1-15 of PTPN11, revealing a novel 3-bp deletion mutation and 10 recurrent missense mutations in 18 patients. Clinical assessment showed that 1) the growth pattern was similar in mutation-positive and mutation-negative patients, with no significant difference in birth length [-0.6 ± 2.2 SD (n = 10) vs. -0.6 ± 1.4 SD (n = 21); P = 0.95], childhood height [-2.6 ± 1.1 SD (n = 14) vs. -2.1 ± 1.6 SD (n = 23); P = 0.28], or target height [-0.4 ± 0.9 SD (n = 14) vs. -0.2 ± 0.7 SD (n = 17); P = 0.52]; 2) pulmonary valve stenosis was more frequent in mutation-positive patients than in mutation-negative patients (10 of 18 vs. 6 of 27; P = 0.02), as was atrial septal defect (10 of 18 vs. 4 of 27; P = 0.005), whereas hypertrophic cardiomyopathy was present in five mutation-negative patients only; and 3) other features were grossly similar in the prevalence between mutation-positive and mutation-negative patients, but hematological abnormalities, such as bleeding diathesis and juvenile myelomonocytic leukemia, were exclusively present in mutation-positive patients (5 of 18 vs. 0 of 27; P = 0.007). The results suggest that PTPN11 mutations account for approximately 40% of Noonan syndrome patients, as has been reported previously. Furthermore, assessment of clinical features, in conjunction with data reported previously, implies that the type of cardiovascular lesions and the occurrence of hematological abnormalities are different in mutation-positive and mutation-negative patients, whereas the remaining findings are similar in the two groups of patients.

AB - We report on PTPN11 (protein-tyrosine phosphatase, nonreceptor type 11) mutation analysis and clinical assessment in 45 patients with Noonan syndrome. Sequence analysis was performed for all of the coding esons 1-15 of PTPN11, revealing a novel 3-bp deletion mutation and 10 recurrent missense mutations in 18 patients. Clinical assessment showed that 1) the growth pattern was similar in mutation-positive and mutation-negative patients, with no significant difference in birth length [-0.6 ± 2.2 SD (n = 10) vs. -0.6 ± 1.4 SD (n = 21); P = 0.95], childhood height [-2.6 ± 1.1 SD (n = 14) vs. -2.1 ± 1.6 SD (n = 23); P = 0.28], or target height [-0.4 ± 0.9 SD (n = 14) vs. -0.2 ± 0.7 SD (n = 17); P = 0.52]; 2) pulmonary valve stenosis was more frequent in mutation-positive patients than in mutation-negative patients (10 of 18 vs. 6 of 27; P = 0.02), as was atrial septal defect (10 of 18 vs. 4 of 27; P = 0.005), whereas hypertrophic cardiomyopathy was present in five mutation-negative patients only; and 3) other features were grossly similar in the prevalence between mutation-positive and mutation-negative patients, but hematological abnormalities, such as bleeding diathesis and juvenile myelomonocytic leukemia, were exclusively present in mutation-positive patients (5 of 18 vs. 0 of 27; P = 0.007). The results suggest that PTPN11 mutations account for approximately 40% of Noonan syndrome patients, as has been reported previously. Furthermore, assessment of clinical features, in conjunction with data reported previously, implies that the type of cardiovascular lesions and the occurrence of hematological abnormalities are different in mutation-positive and mutation-negative patients, whereas the remaining findings are similar in the two groups of patients.

UR - http://www.scopus.com/inward/record.url?scp=3242739935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242739935&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-032091

DO - 10.1210/jc.2003-032091

M3 - Article

VL - 89

SP - 3359

EP - 3364

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -